Antihypertensive and antihyperglycemic effects of combinations of losartan with metformin and/or glibenclamide in desoxycorticosterone acetate and streptozotocin-induced hypertensive diabetic rats

Table 7 Effects of losartan, metformin and glibenclamide on heart rate (bpm) of DOCA + STZ hypertensive diabetic rats

Treatment	Initial	Week 1	Week 2	Week 3	Week 4	Week 8
Normal Control	355.33 ± 18.48	330.00 ± 12.00	342.00 ± 12.17	342.67 ± 5.78	338.00 ± 6.51	318.67 ± 8.37
HD Control	351.33 ± 10.65	367.00 ± 10.07	374.00 ± 7.00	374.67 ± 4.10	380.00 ± 4.10^*	381.67 ± 12.02^*
HD + LOS + MET	396.00 ± 6.66	345.67 ± 14.67	327.00 ± 24.79	324.33 ± 6.67	314.33 ± 1.67^#	315.67 ± 6.84^#
HD + LOS + GLB	382.00 ± 13.80	371.33 ± 9.33	371.00 ± 2.00	353.00 ± 41.00	321.67 ± 12.35^#	322.67 ± 0.88^#
HD + LOS + MET + GLB	399.00 ± 9.45	340.33 ± 17.57	354.33 ± 12.78	324.33 ± 6.67	312.67 ± 1.67^#	324.00 ± 4.93^#

All values are expressed as mean ± SEM (n = 5). *P < 0.05 when compared with normal control; ^#P < 0.05 when compared with hypertensive diabetic control. (HD Control Hypertensive Diabetic Control, HD Hypertensive Diabetic Rats, LOS Losartan, MET Metformin, GLB Glibenclamide)

ISSN: 2233-7660